Clinical Trials Logo

Prostatic Cancer Metastatic clinical trials

View clinical trials related to Prostatic Cancer Metastatic.

Filter by:
  • None
  • Page 1

NCT ID: NCT03389451 Active, not recruiting - Prostate Cancer Clinical Trials

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

Start date: February 16, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging. If this works, prostate cancer treatments can be prescribed that match the location of the disease. PSMA is radiolabeled with Gallium-68 (Ga-68). This means a participant receives a small dose of radiation from the drug - less than the annual radiation limit for a medical worker. To test this new drug, participants will receive an injection of Ga-68 PSMA and then have a PET scan. This PET scan, and the reported results, will be entered into the medical record and shared with the treating oncologists.